Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 20/20 | 0.62 |
| ▸ | CYBB | P04839 | 9/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 8/20 | 0.59 |
| ▸ | NOX5 | Q96PH1 | 7/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931623 | 1.00 | NOX4 (0.62) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29522734 | 0.93 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29523224 | 0.93 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931624 | 0.93 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931612 | 0.93 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29522841 | 0.92 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931677 | 0.92 | NOX4 (0.57) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931650 | 0.92 | NOX4 (0.58) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29523500 | 0.92 | NOX4 (0.58) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931692 | 0.92 | NOX4 (0.60) | NOX4CYBBNOX1NOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117769427-A | Modified nucleosides and nucleotide analogues as antiviral agents for coronaviruses and other viruses | 埃默里大学 | 2024-03-26 | — | — | CN | disclosed |
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2022-09-01 | — | — | US | disclosed |
| CN-114026067-A | Peptide mimetics for the treatment of coronavirus and picornavirus infections | 埃默里大学 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273753-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | NOX4 4661/4885CYBB 4765/4885NOX1 3441/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | NOX4 4650/4885CYBB 4793/4885NOX1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.